Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
Authors
Keywords
-
Journal
Clinical Pharmacology in Drug Development
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-12-11
DOI
10.1002/cpdd.762
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Obesity and nonalcoholic fatty liver disease: current perspectives
- (2018) Raiya Sarwar et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers
- (2016) R. Pencek et al. DIABETES OBESITY & METABOLISM
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
- (2016) Frederik Nevens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
- (2015) Gideon M. Hirschfield et al. GASTROENTEROLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells
- (2015) Jialin He et al. Molecular Cancer
- FXR induces SOCS3 and suppresses hepatocellular carcinoma
- (2015) Fei Guo et al. Oncotarget
- The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice
- (2014) TinaMarie Lieu et al. GASTROENTEROLOGY
- Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
- (2013) Howard C. Masuoka et al. Annals of the New York Academy of Sciences
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- The TGR5 receptor mediates bile acid–induced itch and analgesia
- (2013) Farzad Alemi et al. JOURNAL OF CLINICAL INVESTIGATION
- The Role of Bile After Roux-en-Y Gastric Bypass in Promoting Weight Loss and Improving Glycaemic Control
- (2012) Dimitri J. Pournaras et al. ENDOCRINOLOGY
- Loss of FXR Protects against Diet-Induced Obesity and Accelerates Liver Carcinogenesis inob/obMice
- (2012) Yanqiao Zhang et al. MOLECULAR ENDOCRINOLOGY
- Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
- (2012) Anna C. Calkin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
- (2011) Eric T. Sawey et al. CANCER CELL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started